Nuvalent, Inc. (NUVL)

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

No competitor list for this company yet.

• 6/9/2026POSITIVE
  JM Smucker Moves on Profit Beat; Vail Resorts Down on Full Year Guidance Cut | Stock Movers

  GSK has agreed to acquire Nuvalent Inc. for $10.6 billion, a move that sent Nuvalent shares higher. The US-based biotechnology firm is recognized for its development of treatments targeting lung cancer. This acquisition highlights the strategic value of Nuvalent's pipeline and its potential in the oncology space. For investors, this represents a significant premium and a successful exit for Nuvalent shareholders, underscoring the ongoing M&A activity in the biotech sector.

• 3/17/2026NEGATIVE
  This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

  An investor has divested $104 million worth of Nuvalent Inc. stock, coinciding with a nearly 30% surge in the cancer drug developer's share price. Nuvalent is focused on advancing precision oncology treatments for drug-resistant cancers. While the company's pipeline progress is a positive driver, the significant sell-off by a major holder suggests potential concerns or profit-taking, which could temper further upside momentum for the stock.

• 2/23/2026NEGATIVE
  Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

  A major biotech fund has dumped its $84 million position in Nuvalent, a company developing targeted cancer therapies. This significant sell-off follows a 29% surge in the stock's value, indicating a substantial profit-taking move by an institutional investor. While the stock's past performance has been robust, such a large block sale from a single entity, often considered "smart money," can be interpreted as a bearish signal by the market. This action raises concerns that the stock may have reached a near-term peak, potentially triggering follow-on selling from other investors and creating downward pressure on the share price. The market will now watch to see how well this large supply of shares is absorbed.